Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
McKinsey
Deloitte
Harvard Business School
Mallinckrodt
Daiichi Sankyo
Fuji
Cantor Fitzgerald
McKesson
US Department of Justice

Generated: August 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204485

« Back to Dashboard
NDA 204485 describes VASOSTRICT, which is a drug marketed by Par Sterile Products and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the VASOSTRICT profile page.

The generic ingredient in VASOSTRICT is vasopressin. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vasopressin profile page.

Summary for NDA: 204485

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Pituitary)
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 204485

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VASOSTRICT
vasopressin
SOLUTION;IV (INFUSION) 204485 NDA Par Pharmaceutical, Inc. 42023-164 42023-164-25 25 VIAL in 1 CARTON (42023-164-25) > 1 mL in 1 VIAL (42023-164-01)
VASOSTRICT
vasopressin
SOLUTION;IV (INFUSION) 204485 NDA Par Pharmaceutical, Inc. 42023-190 42023-190-01 1 VIAL in 1 CARTON (42023-190-01) > 10 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;IV (INFUSION)Strength20UNITS/ML (20UNITS/ML)
Approval Date:Apr 17, 2014TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jan 30, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES
Patent:► SubscribePatent Expiration:Jan 30, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;IV (INFUSION)Strength200UNITS/10ML (20UNITS/ML)
Approval Date:Dec 17, 2016TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jan 30, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Colorcon
Accenture
Cerilliant
Chinese Patent Office
Mallinckrodt
McKinsey
McKesson
Merck
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot